Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Opts Out Of Targacept Schizophrenia Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Targacept says it will continue to develop its schizophrenia drug, even though AstraZeneca has opted not to move forward.

You may also be interested in...



Top Neuroscience Partnering Opportunities: Seeking To Alter Treatment Paradigms

Neuroscience track at the Therapeutic Area Partnerships conferencewill feature novel candidates for Alzheimer’s, depression, traumatic brain injury, Fragile X syndrome and post-herpetic neuralgia.

Deals Of The Week Untangles The String Of Pearls

In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.

Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute

The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.

Related Content

Topics

UsernamePublicRestriction

Register

PS072262

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel